Sulfadoxine-Pyrimethamine
Drug25 mg/kg po once on day 0
Other names: Fansidar, Roche
NCT Number: NCT00852371
This will be a randomized, single-blinded, placebo-controlled trial to evaluate the efficacy, safety and tolerability of antimalarial regimens in healthy schoolchildren. The primary objective of the study is to compare the efficacy of different combination antimalarial regimens, including amodiaquine + sulfadoxine-pyrimethamine (AQ+SP), dihydroartemisinin-piperaquine (DP), and placebo, to SP for intermittent preventive treatment (IPT) in schoolchildren, as measured by risk of parasitaemia (unadjusted by genotyping) after 42 days of follow-up. This will assess both the efficacy for treatment of asymptomatic infections and the efficacy for prevention of new infections.
Looking for future studies?
Notify Me8 year–13 year
All sexes
Interventional
Phase 3
The study will be carried out among children aged ≥ 8 to < 14 years (boys) and ≥ 8 to < 12 years (girls) attending primary schools in Tororo district. Schools will be selected using convenience sampling with the assistance of the district and the education sector. The target population includes children attending primary schools in Uganda. The accessible population includes the children attending the participating primary schools in classes 3-7 in Tororo district. Children who meet the selection criteria for participation in the study will be randomized to treatment with one of the four study regimens and will be followed for 42 days. Repeat evaluations will be performed on days 1, 2, 3, 7, 14, 28, and 42 (and any unscheduled day that a student is ill) and will include assessment for the occurrence of adverse events. Treatment efficacy outcomes will be assessed using revised WHO outcome classification criteria. Acceptability of treatment regimens will be assessed using a questionnaire administered to participating students on day 7. The primary outcome measure is risk of parasitaemia (unadjusted by genotyping) after 42 days of follow-up.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
25 mg/kg po once on day 0
Other names: Fansidar, Roche
Amodiaquine: 10 mg/kg po daily for 3 days (on days 0, 1, 2) SP: 25 mg/kg po once on day 0
Other names: Camoquin, Pfizer, Fansidar, Roche
2.1/17.1 mg/kg daily for three days (on days 0, 1, 2)
Other names: Duocotexcin, Holley Cotec Pharmaceuticals
dosed as for amodiaquine (10mg/kg po daily on days 1, 2)
Other names: No active ingredient
Time frame: after 42 days of follow-up
Proportion of participants whose thick blood smears that are positive for asexual parasites
Time frame: after 42 days of follow-up
Proportion of participants whose thick blood smears that are positive with the same asexual parasites at baseline and on the day of failure at genotyping
Time frame: after 42 days of follow-up
Proportion of participants whose thick blood smears that are positive for new asexual parasites on day of failure at genotyping
Time frame: Over 42 days of follow-up
Proportion of children who were parasitaemia at enrollment, with subsequent fever and a positive thick blood smear for asexual parasites on the day of failure during follow-up
Time frame: Between day 0 to day 42
Haemoglobin measured in g/dL; Mean change in haemoglobin calculated as the difference in mean haemoglobin (g/dL) on Day 42 - Day 0, in children treated with the different antimalarial regimens
Time frame: over 42 days of follow-up
Any untoward medical occurrence in a participant taking study medication after 14 and 42 days of follow up leading to death, disability, hospitalization or extended hospitalization
Time frame: on day 7
Perceived willingness to take study medication as routine preventive treatment
Time frame: after 42 days of follow-up
Proportion of children who were parasitaemia at enrollment, with subsequent fever and a positive thick blood smear for asexual parasites on the day of failure during follow-up
London School of Hygiene and Tropical Medicine
Other
IPT in Schoolchildren: Comparison of the Efficacy, Safety, and Tolerability of Antimalarial Regimens in Uganda
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05978037
Infections, Malaria
Oxford, Oxfordshire, United Kingdom
View Trial DetailsNCT05891236
Infections, Malaria
Baltimore, Maryland, United States
View Trial DetailsNCT07060508
Infections, Malaria
Faladié, Koulikoro, Mali
View Trial DetailsNCT04529434
Diarrhoea;Acute, Infections
Dar Es Salaam, Mtwara, Tanzania
View Trial Details